Literature DB >> 33505382

Non-synonymous Substitutions in HIV-1 GAG Are Frequent in Epitopes Outside the Functionally Conserved Regions and Associated With Subtype Differences.

Babatunde A Olusola1, David O Olaleye1, Georgina N Odaibo1.   

Abstract

In 2019, 38 million people lived with HIV-1 infection resulting in 690,000 deaths. Over 50% of this infection and its associated deaths occurred in Sub-Saharan Africa. The West African region is a known hotspot of the HIV-1 epidemic. There is a need to develop an HIV-1 vaccine if the HIV epidemic would be effectively controlled. Few protective cytotoxic T Lymphocytes (CTL) epitopes within the HIV-1 GAG (HIV_gagconsv) have been previously identified to be functionally conserved among the HIV-1 M group. These epitopes are currently the focus of universal HIV-1 T cell-based vaccine studies. However, these epitopes' phenotypic and genetic properties have not been observed in natural settings for HIV-1 strains circulating in the West African region. This information is critical as the usefulness of universal HIV-1 vaccines in the West African region depends on these epitopes' occurrence in strains circulating in the area. This study describes non-synonymous substitutions within and without HIV_gagconsv genes isolated from 10 infected Nigerians at the early stages of HIV-1 infection. Furthermore, we analyzed these substitutions longitudinally in five infected individuals from the early stages of infection till after seroconversion. We identified three non-synonymous substitutions within HIV_gagconsv genes isolated from early HIV infected individuals. Fourteen and nineteen mutations outside the HIV_gagconsv were observed before and after seroconversion, respectively, while we found four mutations within the HIV_gagconsv. These substitutions include previously mapped CTL epitope immune escape mutants. CTL immune pressure likely leaves different footprints on HIV-1 GAG epitopes within and outside the HIV_gagconsv. This information is crucial for universal HIV-1 vaccine designs for use in the West African region.
Copyright © 2021 Olusola, Olaleye and Odaibo.

Entities:  

Keywords:  HIV cure; HIV-1 GAG; HIV-1 subtypes; MHR; non-synonymous substitutions

Year:  2021        PMID: 33505382      PMCID: PMC7829476          DOI: 10.3389/fmicb.2020.615721

Source DB:  PubMed          Journal:  Front Microbiol        ISSN: 1664-302X            Impact factor:   5.640


  80 in total

1.  HIV vaccine design and the neutralizing antibody problem.

Authors:  Dennis R Burton; Ronald C Desrosiers; Robert W Doms; Wayne C Koff; Peter D Kwong; John P Moore; Gary J Nabel; Joseph Sodroski; Ian A Wilson; Richard T Wyatt
Journal:  Nat Immunol       Date:  2004-03       Impact factor: 25.606

2.  HLA-B*35: 05 is a protective allele with a unique structure among HIV-1 CRF01_AE-infected Thais, in whom the B*57 frequency is low.

Authors:  Masahiko Mori; Nuanjun Wichukchinda; Reiko Miyahara; Archawin Rojanawiwat; Panita Pathipvanich; Tomoyuki Maekawa; Toshiyuki Miura; Philip Goulder; Michio Yasunami; Koya Ariyoshi; Pathom Sawanpanyalert
Journal:  AIDS       Date:  2014-04-24       Impact factor: 4.177

3.  Replication and compartmentalization of HIV-1 in kidney epithelium of patients with HIV-associated nephropathy.

Authors:  Daniele Marras; Leslie A Bruggeman; Feng Gao; Nozomu Tanji; Mahesh M Mansukhani; Andrea Cara; Michael D Ross; G Luca Gusella; Gary Benson; Vivette D D'Agati; Beatrice H Hahn; Mary E Klotman; Paul E Klotman
Journal:  Nat Med       Date:  2002-05       Impact factor: 53.440

4.  HIV-1 gag cytotoxic T lymphocyte epitopes vary in presentation kinetics relative to HLA class I downregulation.

Authors:  Arumugam Balamurugan; Ayub Ali; Julie Boucau; Sylvie Le Gall; Hwee L Ng; Otto O Yang
Journal:  J Virol       Date:  2013-06-05       Impact factor: 5.103

5.  CD8+ TCR Bias and Immunodominance in HIV-1 Infection.

Authors:  Henrik N Kløverpris; Reuben McGregor; James E McLaren; Kristin Ladell; Mikkel Harndahl; Anette Stryhn; Jonathan M Carlson; Catherine Koofhethile; Bram Gerritsen; Can Keşmir; Fabian Chen; Lynn Riddell; Graz Luzzi; Alasdair Leslie; Bruce D Walker; Thumbi Ndung'u; Søren Buus; David A Price; Philip J Goulder
Journal:  J Immunol       Date:  2015-04-24       Impact factor: 5.422

6.  Virological outcome after structured interruption of antiretroviral therapy for human immunodeficiency virus infection is associated with the functional profile of virus-specific CD8+ T cells.

Authors:  Marybeth Daucher; David A Price; Jason M Brenchley; Laurie Lamoreaux; Julia A Metcalf; Catherine Rehm; Elizabeth Nies-Kraske; Elizabeth Urban; Christian Yoder; Diane Rock; Julie Gumkowski; Michael R Betts; Mark R Dybul; Daniel C Douek
Journal:  J Virol       Date:  2008-01-30       Impact factor: 5.103

7.  Signature pattern analysis: a method for assessing viral sequence relatedness.

Authors:  B Korber; G Myers
Journal:  AIDS Res Hum Retroviruses       Date:  1992-09       Impact factor: 2.205

8.  The hypervariable HIV-1 capsid protein residues comprise HLA-driven CD8+ T-cell escape mutations and covarying HLA-independent polymorphisms.

Authors:  Hayley Crawford; Philippa C Matthews; Malinda Schaefer; Jonathan M Carlson; Alasdair Leslie; William Kilembe; Susan Allen; Thumbi Ndung'u; David Heckerman; Eric Hunter; Philip J R Goulder
Journal:  J Virol       Date:  2010-11-24       Impact factor: 5.103

9.  High frequency of transmitted HIV-1 Gag HLA class I-driven immune escape variants but minimal immune selection over the first year of clade C infection.

Authors:  Kamini Gounder; Nagavelli Padayachi; Jaclyn K Mann; Mopo Radebe; Mammekwa Mokgoro; Mary van der Stok; Lungile Mkhize; Zenele Mncube; Manjeetha Jaggernath; Tarylee Reddy; Bruce D Walker; Thumbi Ndung'u
Journal:  PLoS One       Date:  2015-03-17       Impact factor: 3.240

10.  Multiplex RT-PCR amplification of HIV genes to create a completely autologous DC-based immunotherapy for the treatment of HIV infection.

Authors:  Irina Tcherepanova; Jason Harris; Aijing Starr; Jaclyn Cleveland; Helen Ketteringham; David Calderhead; Joe Horvatinovich; Don Healey; Charles A Nicolette
Journal:  PLoS One       Date:  2008-01-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.